Lily Rin-Laures has managed global intellectual property portfolios and provided comprehensive strategic counseling for a variety of clients ranging from startups to Fortune 500 companies. She draws on her experience as former General Counsel of a publicly held biotechnology company to assist clients to achieve their intellectual property and business goals. A substantial part of her practice involves counseling clients on patent strategy relating to new pharmaceutical/biotechnology product development, product life cycle management, and the interface with FDA regulations and related exclusivity provisions.
Dr. Rin-Laures’ practice involves patent prosecution, freedom-to-operate searches, validity and infringement opinions, patent opposition proceedings, reexamination, protests, interferences, and appeals to the Federal Circuit, where she clerked from 1992-1993. Dr. Rin-Laures also advises clients in a variety of transactions from due diligence to term sheet negotiations and drafting complex agreements. Her experience includes agreements dealing with licenses, collaborations and other strategic alliances, sponsored research, technology and material transfer.
In her patent prosecution practice, Dr. Rin-Laures focuses on biotechnology and traditional pharmaceutical and medical technologies. Representative examples of her technology experience include:
- Antibodies
- Antisense and RNAi
- Recombinant biological drug products, including hemopoietic factors, growth factors, chemokines, neurotrophic factors, cellular adhesion molecules, enzymes, macrophage and neutrophil products, and bacterial antigens
- Small peptides and chemically modified derivatives
- Vaccines and immune therapies
- Chemical pharmaceutical products
- Pharmaceutical formulations, including aqueous compositions, lyophilized compositions, hydrogels and transdermal delivery
- Therapeutic methods using traditional pharmaceuticals or biologicals
- Processes and vectors for recombinant protein production in bacteria, cell lines and plants
- Diagnostic methods, e.g., for cancer, infection and autoimmune diseases
- GMO plants
Dr. Rin-Laures was named one of "Forty Illinois Attorneys Under 40 to Watch,” a list of the state’s most talented and well-regarded young lawyers published by the Law Bulletin Publishing Company, and has been voted an “Illinois Super Lawyer” for a number of years, a list which identifies the top five percent of the lawyers in Illinois based on a survey and research conducted by Law & Politics.
In the past she was a frequent speaker on patent and licensing issues. Presentations include "Mastering Hot New Issues that Arise from New Technology" at Complex Intellectual Property Licensing seminar in Chicago, in April 2006 and on "Creating an Intellectual Property Framework for your Collaboration" at National Pharmaceutical and Biotech IP Licensing and Dealmaking Forum in Boston, in June of 2005. Dr. Rin-Laures has also written articles including "Industries Await Exemption Verdict", published in Managing IP, No. 148, April 2005, by Patel and Rin-Laures, and "Incentives to foster new antibiotics are proposed", published in The National Law Journal, August 29, 2005, by Rin-Laures and Flowers.
Dr. Rin-Laures was the youngest woman graduate at Johns Hopkins University where she received her B.A. in Chemistry, with honors, in 1984. She completed her medical school studies in 1988 when she received her M.D. from Northwestern University Medical School. Dr. Rin-Laures graduated in 1992 from Harvard Law School, cum laude, where she was Executive Editor and Managing Editor of Harvard Journal of Law and Technology and Editor-in-Chief of "Recent Developments in Health Law" in Law, Medicine & Health Care. She served a clerkship with the Hon. S. Jay Plager at the Court of Appeals for the Federal Circuit after graduation from law school.
In 2001-2002, while on leave of absence from the firm, Dr. Rin-Laures served as General Counsel of Hyseq Pharmaceuticals, Inc. (now known as Nuvelo, Inc.). In her position as General Counsel, Dr. Rin-Laures was responsible for settling litigation and negotiating numerous strategic alliance and license agreements.
REPRESENTATIVE MATTERS
Adams (Monsanto)* v. Leemans (Bayer CropSciences)
U.S. Patent and Trademark Office Board of Patent Appeals and Interferences
Case Type(s): Patent Interference
Area(s) of practice: Biotechnology
American Home Products Corporation v. The Upjohn Company*
U.S. District Court, District of New Jersey
Case Type(s): Patent Infringement
Area(s) of practice: Pharmaceuticals
Barton v. Fischhoff* (Monsanto) v. Adang (Mycogen Plant Science)
U.S. Patent Office Board of Patent Appeals and Interferences
Case Type(s): Patent Interference
Area(s) of practice: Biotechnology
Chee (Affymetrix) v. Drmanac (Hyseq)*
U.S. Patent and Trademark Office Board of Patent Appeals and Interferences
Case Type(s): Patent Interference, Appeal
Area(s) of practice: Biotechnology
Conflict re: Amgen Inc*
the Commissioner of Patents, Canadian Intellectual Property Office
Case Type(s): Conflict
Area(s) of practice: Pharmaceuticals, Biotechnology
Elsbach (Monsanto)* v. Scott
U.S. Patent Office Board of Patent Appeals and Interferences
Case Type(s): Patent Interference, Appeal
Area(s) of practice: Pharmaceuticals, Biotechnology
Grinna* v. Marra
U.S. Patent Office Board of Patent Appeals and Interferences
Area(s) of practice: Pharmaceuticals
Masinovsky* v. Newman v. Rice
U.S. Patent Office Board of Patent Appeals and Interferences
Case Type(s): Patent Interference
Area(s) of practice: Biotechnology
McDonald v. Miyazaki*
U.S. Patent Office Board of Patent Appeals and Interferences
Area(s) of practice: Biotechnology, Pharmaceuticals
Opposition and Appeal on behalf of Amgen Inc.* re: Genentech
Boards of Appeal of the European Patent Office
Area(s) of practice: Biotechnology, Pharmaceuticals
Opposition and Appeal re: Amgen Inc.*
Boards of Appeal of the European Patent Office
Case Type(s): Opposition, Appeal
Area(s) of practice: Biotechnology, Pharmaceuticals
Opposition on behalf of ICOS Corporation* re: Protein Design Labs, Inc.
Boards of Appeal of the European Patent Office
Area(s) of practice: Biotechnology, Pharmaceuticals
Opposition on behalf of Kirin Brewery Co. Ltd.* re: Genentech
Australian Patent Office
Area(s) of practice: Biotechnology, Pharmaceuticals
Opposition on behalf of XOMA Ltd.* re: Protein Design Labs, Inc.
Boards of Appeal of the European Patent Office
Area(s) of practice: Biotechnology, Pharmaceuticals
*Party Represented
